SGLT2inhibitors reduce the risk of kidney disease progression, hospitalization forHF, and CV events.32 SGLT2 inhibitors are recommended for most patients withT2D and CKD with few exceptions. The gene discussed is SLC5A2; the disease is chronic kidney disease.